


WHAT IS CLAIMED IS:

1. A topical veterinary composition for treating or preventing a parasitic infection or infestation in an animal selected from a cat and a dog, wherein said composition is in the form of a spot-on composition for application to a localized area on an animal, said composition comprising:

a) 1 to 25% (w/v) of at least one isoxazoline active agent of Formula (I):



wherein:

A¹, A², A³, A⁴, A⁵ and A⁶ are independently selected from the group consisting of CR³ and N, provided that at most 3 of A¹, A², A³, A⁴, A⁵ and A⁶ are N;

B¹, B² and B³ are independently selected from the group consisting of CR² and N;

W is O or S;

R¹ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl or C₄-C₇ cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R⁶;

each R² is independently H, halogen, C₁-C₆ alkyl, C₁-C₆haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ alkylthio, C₁-C₆haloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆haloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆haloalkylsulfonyl, C₁-C₆ alkylamino, C₂-C₆ dialkylamino, C₂-C₄ alkoxycarbonyl, —CN or —NO₂;

each R³ is independently H, halogen, C₁-C₆ alkyl, C₁-C₆haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ alkylthio, C₁-C₆haloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆haloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆haloalkylsulfonyl, C₁-C₆ alkylamino, C₂-C₆ dialkylamino, —CN or —NO₂;

R⁴ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl, C₄-C₇ cycloalkylalkyl, C₂-C₇ alkylcarbonyl or C₂-C₇ alkoxy carbonyl;

R⁵ is H, OR¹⁰, NR¹¹R¹² or Q¹; or C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl or C₄-C₇ cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R⁷; or

R⁴ and R⁵ are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents independently selected from the group consisting of C₁-C₂ alkyl, halogen, —CN, —NO₂ and C₁-C₂ alkoxy;

each R⁶ is independently halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ alkylsulfonyl, —CN or —NO₂;

each R⁷ is independently halogen; C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₇ alkylcarbonyl, C₂-C₇ alkoxy carbonyl, C₂-C₇ alkylaminocarbonyl, C₃-C₉ dialkylaminocarbonyl, C₂-C₇ haloalkylcarbonyl, C₂-C₇ haloalkoxy carbonyl, C₂-C₇ haloalkylaminocarbonyl, C₃-C₉ dihaloalkylaminocarbonyl, hydroxy, —NH₂, —CN or —NO₂; or Q²;

each R⁸ is independently halogen, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₁-C₆ alkylamino, C₂-C₆ dialkylamino, C₂-C₄ alkoxy carbonyl, —CN or NO₂;

each R⁹ is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₁-C₆ alkylamino, C₂-C₆ dialkylamino, —CN, —NO₂, phenyl or pyridinyl;

R¹⁰ is H; or C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl or C₄-C₇ cycloalkylalkyl, each optionally substituted with one of more halogen;

R¹¹ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl, C₄-C₇ cycloalkylalkyl, C₂-C₇ alkylcarbonyl or C₂-C₇ alkoxy carbonyl;

R^{12} is H; Q3; or C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, C_4 - C_7 alkylcycloalkyl or C_4 - C_7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R^7 ; or

R^{11} and R^{12} are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents independently selected from the group consisting of C_1 - C_2 alkyl, halogen, —CN, —NO₂ and C_1 - C_2 alkoxy;

Q^1 is a phenyl ring, a 5- or 6-membered heterocyclic ring, or an 8-, 9- or 10-membered fused bicyclic ring system optionally containing one to three heteroatoms selected from up to 1 O, up to 1 S and up to 3 N, each ring or ring system optionally substituted with one or more substituents independently selected from R^8 ;

each Q^2 is independently a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R^9 ;

Q^3 is a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R^9 ; and n is 0, 1 or 2; and

b) a pharmaceutically acceptable carrier that is suitable for the application to the skin of an animal; and wherein the carrier comprises dimethyl isosorbide.

2. The topical veterinary composition of claim 1, wherein:

W is O;

R^4 is H or C_1 - C_6 alkyl;

R^5 is $-\text{CH}_2\text{C}(\text{O})\text{NHCH}_2\text{CF}_3$;

each of A^1 , A^2 , A^3 , A^4 , A^5 and A^6 is CH;

R^1 is C_1 - C_6 alkyl each optionally substituted with one or more substituents independently selected from R^6 ;

R^6 is halogen or C_1 - C_6 alkyl; and

B^1 , B^2 , and B^3 are independently CH, C-halogen, C- C_1 - C_6 alkyl, C- C_1 - C_6 haloalkyl, or C- C_1 - C_6 alkoxy.

3. The topical veterinary composition of claim 1, wherein:

W is O;

R¹ is CF₃;

B² is CH;

B¹ is C-Cl;

B³ is C-CF₃;

each of A¹, A², A³, A⁴, A⁵ and A⁶ is CH;

R⁴ is H; and

R⁵ is -CH₂C(O)NHCH₂CF₃.

4. The topical veterinary composition of claim 1, wherein the pharmaceutically acceptable carrier further comprises a solvent selected from glycerol formal, diisopropyl adipate (DIPA), isopropyl palmitate, silicone fluid, propylene glycol (or other aliphatic dihydric alcohols), propylene glycol esters, alkyl esters of dicarboxylic acids, and esters or diesters of fatty acid, or combinations thereof.

5. The topical veterinary composition of claim 1, wherein the pharmaceutically acceptable carrier further comprises a dialkyl ester of a dicarboxylic acid.

6. The topical veterinary composition of claim 5, wherein the dialkyl ester of a dicarboxylic acid is diethyl sebacate.

7. The topical veterinary composition of any one of claims 1 to 6, further comprising at least a second active agent.

8. The topical veterinary composition of claim 7, wherein the at least second active agent is an avermectin or milbemycin.

9. The topical veterinary composition of claim 8, wherein the avermectin or milbemycin is eprinomectin, ivermectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, or moxidectin.

10. The topical veterinary composition of claim 7, wherein the at least second active agent is an insect growth regulator.

11. The topical veterinary composition of claim 10, wherein the insect growth regulator is (S)-methoprene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, or novaluron.

12. The topical veterinary composition of claim 7, wherein the at least second active agent is an anthelmintic active agent selected from thiabendazole, oxbendazole, mebendazole, fenbendazole, oxfendazole, albendazole, triclabendazole, febantel, levamisole, pyrantel, morantel, praziquantel, closantel, clorsulon, an amino acetonitrile active agent, or an aryloazol-2-yl cyanoethylamino active agent.

13. The topical veterinary composition of claim 1, wherein the composition comprises 5 to 15% (w/v) of the compound of formula (I).

14. The topical veterinary composition of claim 1, wherein the isoxazoline active agent is an enantiomer of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide.

15. The topical veterinary composition of any one of claims 1 to 14, for use in the treatment or prevention of a parasitic infestation or infection in a cat or a dog.

16. The topical veterinary composition of any one of claims 1 to 14 for use according to claim 15, wherein the composition is a spot-on composition, and wherein the volume of the composition is 0.1 to 10 ml.

17. The topical veterinary composition of any one of claims 1 to 14 for use according to claim 16, wherein the volume of the composition is 0.1 to 5 ml.

18. The topical veterinary composition of any one of claims 1 to 14 for use according to claim 16, wherein the volume of the composition is 0.1 to 1 ml.

19. The topical veterinary composition of any one of claims 1 to 14 for use according to any one of claims 15 to 18 wherein the animal is a cat.

20. The topical veterinary composition of any one of claims 1 to 14 for use according to claim 19, wherein the volume of the composition is 0.5 ml to 1 ml.

21. The topical veterinary composition of any one of claims 1 to 14 for use according to claim 19, wherein the volume of the composition is 0.5 ml to 2 ml.